series-b
Stage
2017
Founded
4
Investors
About
Topas Therapeutics develops antigen-specific nanoparticle therapies designed to induce immune tolerance by targeting liver endothelial cells, aiming to treat autoimmune and immune-mediated diseases, with clinical programs including Phase 2 trials in celiac disease.
Explore Topas Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.